scholarly journals Ictal heart rate changes and the effects of vagus nerve stimulation for patients with refractory epilepsy

2017 ◽  
Vol Volume 13 ◽  
pp. 2351-2356 ◽  
Author(s):  
Wei Chen ◽  
Fangang Meng
2011 ◽  
Vol 53 (12) ◽  
pp. 1143-1149 ◽  
Author(s):  
KATRIEN JANSEN ◽  
STEVEN VANDEPUT ◽  
MILICA MILOSEVIC ◽  
BERTEN CEULEMANS ◽  
SABINE VAN HUFFEL ◽  
...  

2018 ◽  
Vol 11 (1) ◽  
pp. 80-85
Author(s):  
Rodrigo Marmo da Costa e Souza ◽  
Felipe Ricardo Pereira Vasconcelos De Arruda ◽  
Jose Anderson Galdino Santos ◽  
Jamerson De Carvalho Andrade ◽  
Suellen Mary Marinho Dos Santos Andrade ◽  
...  

2014 ◽  
Vol 7 (6) ◽  
pp. 914-916 ◽  
Author(s):  
Didier Clarençon ◽  
Sonia Pellissier ◽  
Valérie Sinniger ◽  
Astrid Kibleur ◽  
Dominique Hoffman ◽  
...  

Seizure ◽  
2008 ◽  
Vol 17 (5) ◽  
pp. 469-472 ◽  
Author(s):  
Stephan A. Koenig ◽  
Elke Longin ◽  
Nellie Bell ◽  
Julia Reinhard ◽  
Thorsten Gerstner

Author(s):  
Jozsef Constantin Széles ◽  
Stefan Kampusch ◽  
Florian Thürk ◽  
Christian Clodi ◽  
Norbert Thomas ◽  
...  

2021 ◽  
pp. 1-10
Author(s):  
Yifan Zhang ◽  
Xiongfei Wang ◽  
Chongyang Tang ◽  
Yuguang Guan ◽  
Fan Chen ◽  
...  

OBJECTIVE Vagus nerve stimulation (VNS) is an alternative treatment option for individuals with refractory epilepsy, with nearly 40% of patients showing no benefit after VNS and only 6%–8% achieving seizure freedom. It is presently unclear why some patients respond to treatment and others do not. Therefore, identification of biomarkers to predict efficacy of VNS is of utmost importance. The objective of this study was to explore whether genetic variations in genes involved in adenosine kinase (ADK), ecto-5′-nucleotidase (NT5E), and adenosine A1 receptor (A1R) are linked to outcome of VNS in patients with refractory epilepsy. METHODS Thirty single-nucleotide polymorphisms (SNPs), including 9 in genes encoding ADK, 3 in genes encoding NT5E, and 18 in genes encoding A1R, were genotyped in 194 refractory epilepsy patients who underwent VNS. The chi-square test and binary logistic regression were used to determine associations between genetic differences and VNS efficacy. RESULTS A significant association between ADK SNPs rs11001109, rs7899674, and rs946185 and seizure reduction with VNS was found. Regardless of sex, age, seizure frequency and type, antiseizure drug use, etiology, and prior surgical history, all patients (10/10 patients [100%]) with minor allele homozygosity at rs11001109 (genotype AA) or rs946185 (AA) achieved > 50% seizure reduction and 4 patients (4/10 [40%]) achieved seizure freedom. VNS therapy demonstrated higher efficacy among carriers of minor allele rs7899674 (CG + GG) (68.3% vs 48.8% for patients with major allele homozygosity). CONCLUSIONS Homozygous ADK SNPs rs11001109 (AA) and rs946185 (AA), as well as minor allele rs7899674 (CG + GG), may serve as useful biomarkers for prediction of VNS therapy outcome.


Author(s):  
Vinzent Wolf ◽  
Anne Kühnel ◽  
Vanessa Teckentrup ◽  
Julian Koenig ◽  
Nils B. Kroemer

AbstractNon-invasive brain stimulation techniques, such as transcutaneous auricular vagus nerve stimulation (taVNS), have considerable potential for clinical use. Beneficial effects of taVNS have been demonstrated on symptoms in patients with mental or neurological disorders as well as transdiagnostic dimensions, including mood and motivation. However, since taVNS research is still an emerging field, the underlying neurophysiological processes are not yet fully understood, and the replicability of findings on biomarkers of taVNS effects has been questioned. Here, we perform a living Bayesian random effects meta-analysis to synthesize the current evidence concerning the effects of taVNS on heart rate variability (HRV), a candidate biomarker that has, so far, received most attention in the field. To keep the synthesis of evidence transparent and up to date as new studies are being published, we developed a Shiny web app that regularly incorporates new results and enables users to modify study selection criteria to evaluate the robustness of the inference across potential confounds. Our analysis focuses on 17 single-blind studies comparing taVNS versus sham in healthy participants. These newly synthesized results provide strong evidence for the null hypothesis (g = 0.011, CIshortest = [−0.103, 0.125], BF01 = 25.587), indicating that acute taVNS does not alter HRV compared to sham. To conclude, based on a synthesis of the available evidence to date, there is no support for the hypothesis that HRV is a robust biomarker for acute taVNS. By increasing transparency and timeliness, we believe that the concept of living meta-analyses can lead to transformational benefits in emerging fields such as non-invasive brain stimulation.


Sign in / Sign up

Export Citation Format

Share Document